TY - JOUR T1 - Joint estimation of relaxation and diffusion tissue parameters for prostate cancer grading with relaxation-VERDICT MRI JF - medRxiv DO - 10.1101/2021.06.24.21259440 SP - 2021.06.24.21259440 AU - Marco Palombo AU - Vanya Valindria AU - Saurabh Singh AU - Eleni Chiou AU - Francesco Giganti AU - Hayley Pye AU - Hayley C. Whitaker AU - David Atkinson AU - Shonit Punwani AU - Daniel C. Alexander AU - Eleftheria Panagiotaki Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/02/2021.06.24.21259440.abstract N2 - Objectives The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours (VERDICT) is a non-invasive MRI technique that has shown promising results in clinical settings discriminating normal from malignant tissue and Gleason grade 3+3 from 3+4. However, VERDICT currently does not account for the inherent relaxation properties of the tissue, whose quantification could provide additional information and enhance its diagnostic power. The aim of this work is to introduce relaxation-VERDICT (rVERDICT) for prostate, a model for the joint estimation of diffusion-based parameters (e.g. the intracellular volume fraction, fic) and relaxation times (e.g. T2) from a VERDICT MRI acquisition; and to evaluate its repeatability and diagnostic utility for differentiating Gleason grades 3 and 4.Materials and Methods 72 men with suspected prostate cancer (PCa) or undergoing active surveillance were recruited. All men underwent multiparametric MRI (mp-MRI) and VERDICT MRI. Deep neural network was used for ultra-fast fitting of the rVERDICT parameters. 44 men underwent targeted biopsy, which enabled assessment of rVERDICT parameters in differentiating Gleason grades measured with accuracy, F1-score and Cohen’s kappa of a convolutional neural network classifier. To assess the repeatability of the new model, five men were imaged twice.Results The rVERDICT intracellular volume fraction fic discriminated between Gleason grades (5-class classification) with accuracy, F1-score and kappa 8, 7 and 3 percentage points higher than classic VERDICT, and 12, 13 and 24 percentage points higher than the Apparent Diffusion Coefficient (ADC) from mp-MRI. Repeatability of rVERDICT parameters was high (R2=0.74–0.99, coefficient of variation=1%–10% and intraclass correlation coefficient=78%-98%). T2 values estimated with rVERDICT were not significantly different from those estimated with an independent multi-TE acquisition (p>0.05). The deep neural network fitting approach provided stable fitting of all the rVERDICT parameters with dramatic reduction of the processing time (∼35 seconds vs ∼15 minutes using classic VERDICT), enabling on-the-fly rVERDICT map generation.Conclusions The new rVERDICT allows for robust and ultra-fast microstructural estimation of diffusion and relaxation properties of PCa and enables Gleason scoring.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02689271Funding StatementThis work was supported by EP/N021967/1, EP/R006032/1 and by Prostate Cancer UK: Targeted Call 2014: Translational Research St.2, project reference PG14-018-TR2. M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was granted by the London-Surrey Borders Research Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData were collected within the INNOVATE clinical trial, registered with ClinicalTrials.gov identifier NCT02689271 and they are not publicly available. ER -